Guideline on good pharmacovigilance practices (GVP) Module III – Pharmacovigilance inspections (Rev 1):
Introduction:
III.B.
Structures and processes
III.B.1.1.
System and product-related inspections
III.B.1.2.
Routine and “for cause” pharmacovigilance inspections
III.B.1.3.
Pre-authorisation inspections
III.B.1.4.
Post-authorisation inspections
III.B.1.5.
Announced and unannounced inspections
III.B.3.
Sites to be inspected
III.B.4.1.
Routine pharmacovigilance inspections
III.B.4.2.
For cause inspections
III.B.7.
Regulatory actions and sanctions
III.B.8.
Record management and archiving
III.B.9.
Qualification and training of inspectors
III.B.10.
Quality management of pharmacovigilance inspection process
III.C.
Operation of the EU network
III.C.1.
Sharing of information
III.C.2.
Role of the European Medicines Agency
III.C.2.1.
General role of the Agency
III.C.3.
Role of the European Commission
III.C.4.
Role of the Member States
III.C.5.
Role of marketing authorisation holders and applicants